Journal article icon

Journal article

The HIV care cascade for adolescents initiated on antiretroviral therapy in a health district of South Africa: a retrospective cohort study

Abstract:
Background: In South Africa, life expectancy increased considerably after the government introduced its antiretroviral therapy (ART) program in 2004. The impact of the national ART program on life expectancy may be underestimated if child mortality is not accounted for in formal evaluations. Objective: We measured the extent to which life expectancy gains from 2006 to 2017 were attributable to declines in HIV/AIDS mortality, accounting for all age groups, including infants and children. Methods: To calculate life expectancies, we constructed period life tables using age-specific mortality rates estimated by Thembisa, a South Africa-based HIV epidemic model that integrates pediatric HIV data sources. We modeled counterfactual scenarios, a worst-case and best-case, to discern life expectancy gains related to HIV mortality versus other causes of mortality. We reported outcomes as life expectancy gains and life-years saved per person at varying ages. Results: In South Africa, life expectancy at birth was 65.1 years in 2017, compared to 54.0 years in 2006. Of these 11.1 life-years gained, we found that 8.9 life-years were attributable to HIV mortality reductions. In people under 49 years old, most gains were attributable to HIV reduction. Gains from HIV reduction and other causes became equivalent at about age 49. In people over 60, most gains were attributable to causes other than HIV/AIDS reduction. Contribution: This study demonstrated that most life expectancy gains were attributable to declines in HIV mortality following the national ART rollout in South Africa. This analysis tracked life expectancies across age groups, including children, and described their characteristics
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1186/s12879-020-05742-9

Authors

More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0001-6615-9194
More by this author
Role:
Author
ORCID:
0000-0002-3800-3173
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-0418-835X


More from this funder
Funder identifier:
10.13039/501100000269
Grant:
ES/J500112/1
More from this funder
Funder identifier:
10.13039/501100007936
Grant:
155-Hod; 2018/625-TOS
More from this funder
Funder identifier:
10.13039/501100013589
Grant:
0005218
More from this funder
Funder identifier:
10.13039/501100004789
Grant:
161/033; 103/757
More from this funder
Funder identifier:
10.13039/100010661
Grant:
737476


Publisher:
BioMed Central
Journal:
BMC Infectious Diseases More from this journal
Volume:
21
Issue:
1
Pages:
60-60
Article number:
60
Publication date:
2021-01-13
DOI:
EISSN:
1471-2334
ISSN:
1471-2334


Language:
English
Keywords:
Pubs id:
1151270
Local pid:
pubs:1151270
Source identifiers:
W3118498967
Deposit date:
2026-02-12
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP